KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 07/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 114.21M | 75.04M | 15.12M | 1.43M | -- |
| Total Other Revenue | 1.70M | -- | -- | -- | -- |
| Total Revenue | 115.91M | 75.04M | 15.12M | 1.43M | -- |
| Cost of Revenue | 56.73M | 55.39M | 55.74M | 61.20M | 72.06M |
| Gross Profit | 59.18M | 19.65M | -40.63M | -59.77M | -72.06M |
| SG&A Expenses | 200.40M | 187.14M | 157.08M | 135.36M | 108.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 257.12M | 242.53M | 212.83M | 196.56M | 180.34M |
| Operating Income | -141.22M | -167.48M | -197.71M | -195.14M | -180.34M |
| Income Before Tax | -141.22M | -165.32M | -197.12M | -188.87M | -171.38M |
| Income Tax Expenses | -2.78M | 1.46M | 12.81M | 10.65M | 8.49M |
| Earnings from Continuing Operations | -138.44 | -166.79 | -209.92 | -199.53 | -179.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.44M | -166.79M | -209.92M | -199.53M | -179.87M |
| EBIT | -141.22M | -167.48M | -197.71M | -195.14M | -180.34M |
| EBITDA | -139.74M | -166.11M | -196.69M | -194.18M | -179.42M |
| EPS Basic | -2.57 | -3.12 | -3.94 | -3.86 | -3.61 |
| Normalized Basic EPS | -1.65 | -1.94 | -2.33 | -2.31 | -2.17 |
| EPS Diluted | -2.57 | -3.12 | -3.94 | -3.86 | -3.61 |
| Normalized Diluted EPS | -1.65 | -1.94 | -2.33 | -2.31 | -2.17 |
| Average Basic Shares Outstanding | 217.15M | 215.64M | 213.09M | 205.79M | 198.53M |
| Average Diluted Shares Outstanding | 217.15M | 215.64M | 213.09M | 205.79M | 198.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |